Lymphoid leukemia

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Retrieved on: 
星期二, 四月 9, 2024
Histology, Brain, Rituximab, Chronic lymphocytic leukemia, CLL, Lymphoma, Disease, CSF, Central nervous system, SAN, CNS, Patient, PCNSL, BCL2, Cancer, Leukemia, Inflammation, Cerebrospinal fluid, NHL, Lymph, AACR, Proteolysis targeting chimera, Neoplasm, Therapy, MYC, BTK, Myenteric plexus, Lymphoid leukemia, Spleen, Medical imaging

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton’s tyrosine kinase (BTK). The presentation included case studies for two patients, one with CLL with CNS involvement and the other with PCNSL, each demonstrating clinically meaningful responses. The presentation also provided evidence of measurable drug levels in the CNS of multiple patients in the ongoing Phase 1 trial who had CNS tumor involvement. These data were presented by Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, as part of the Major Symposium session Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances at the AACR 2024 Annual Meeting, which is being held from April 5-10, 2024, in San Diego, CA.

Key Points: 
  • The presentation included case studies for two patients, one with CLL with CNS involvement and the other with PCNSL, each demonstrating clinically meaningful responses.
  • The presentation also provided evidence of measurable drug levels in the CNS of multiple patients in the ongoing Phase 1 trial who had CNS tumor involvement.
  • “These data are the first demonstration of clinical activity in the brain of a targeted protein degrader, opening the door for new therapeutic strategies to treat leukemias and lymphomas with CNS involvement,” said Dr. Hansen.
  • “The CLL patient with CNS involvement showed an impressive durable response with NX-5948 as single agent therapy in this setting.

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
星期五, 四月 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting

Retrieved on: 
星期三, 三月 20, 2024
Health, Technology, Health Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Safety, ACS, Pharmacokinetics, BTK, Therapy, MALT1, Lymphoid leukemia, American Chemical Society, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.
  • The oral presentation provided an overview of how Schrödinger leveraged its computational approaches at scale to discover SGR-1505.
  • Reaching a development candidate can take three to six years and typically involves synthesizing up to 5,000 molecules per program.
  • Schrödinger recently completed a Phase 1 study showing that SGR-1505 was well tolerated in a Phase 1 study of 73 healthy volunteers.

Autolus Therapeutics announces publication in Blood Cancer Journal

Retrieved on: 
星期一, 三月 11, 2024
TRBC1, Antibody, Mayo Clinic, Lymphoid leukemia, Thermo Fisher Scientific, TRBC, Bone marrow, Flow cytometry, Vaccine

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1
    Diagnosing leukemic T-cell malignancies poses challenges due to their resemblance to reactive T-cells.
  • In the paper published by Pedro Horna of Mayo Clinic in collaboration with Autolus, the authors introduce a unique approach for identifying T-cell neoplasms by flow cytometry1.
  • This method adopts the recently described monoclonal antibodies targeting TRBC1 and TRBC22, 3, to assess for TRBC-restriction as a surrogate of clonality.
  • The strategy mirrors the routine and broadly adopted analysis of kappa and lambda immunoglobulin chain restriction for the identification of B-cell malignancies.

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
星期二, 三月 5, 2024
BTK, SAN, Education, AACR, Inflammation, Proteolysis targeting chimera, Annual general meeting, Protein, Chemistry, Therapy, Lymphoid leukemia, CNS, Patient, Site, Cancer

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research (AACR) 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.

Key Points: 
  • SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research (AACR) 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.
  • Dr. Hansen’s presentation “NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma” will be featured in the Major Symposium session: Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances that will be held from 10:15 -11:45 a.m. PT on Tuesday, April 9, 2024.
  • Dr. Hansen is also a featured presenter in the Educational session: Chemistry to the Clinic Part 1 of 3: Targeted Protein Degraders: Delivering Degraders to the Site of Action that will be held from 4:45 - 6:15 p.m. PT on Friday, April 5, 2024.

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
星期四, 二月 29, 2024
Neoplasm, CD47, VIVID, CD19, Exercise, Science Translational Medicine, Bone marrow, Lymphoid leukemia, Lupus nephritis, CTA, Biotechnology, Escape Room, Research and development, GLEAM, ANCA, GAAP, Sana, Insulin, Development, Immune system, Regeneration, ASH, CD22, AACR, B cell, Safety, Immunosuppression, Diabetes, Patent, IND, Insurance, Nature Biotechnology, NHL, Cancer, CLL, Contingency, Cell, NHP, Organoid, Autoimmunity, Administration, Cell Stem Cell, Patient, HIP, Nature Communications, ISSCR, C-peptide, Vaccine

The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.

Key Points: 
  • The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
  • Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
星期一, 二月 26, 2024
Neoplasm, Regenerative medicine, CIRM, B-cell lymphoma, Graft-versus-host disease, Investment, TRAC, ADR, CD19, Cytokine release syndrome, Cell, Destiny, HER2, BCMA, Lupus, IPSC, Safety, GAAP, Therapy, Trastuzumab, Pharmacokinetics, Lymphoid leukemia, Patient, NK, Multiple myeloma, SLE, Immunotherapy, Research, CRS, Vaccine

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Total Operating Expenses: For the fourth quarter of 2023, GAAP operating expenses were $49.8 million, including research and development expenses of $31.8 million and general and administrative expenses of $17.9 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of December 31, 2023.
  • ET to review financial and operating results for the quarter and full year ended December 31, 2023.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
星期四, 三月 7, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, BTK, PFS, Hematology, University, Food, Mantle cell lymphoma, BGNE, Lymphocytosis, Safety, MD Anderson Cancer Center, Chronic lymphocytic leukemia, Lymphoid leukemia, Malignancy, Obinutuzumab, Patient, IRC, Follicular lymphoma, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory MAHOGANY ( NCT05100862 ) trial, which is underway.

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory MAHOGANY ( NCT05100862 ) trial, which is underway.
  • The application for R/R FL was also granted Fast Track Designation and Orphan Drug Designation by the FDA.
  • In a recent presentation, BRUKINSA showed sustained PFS benefit versus ibrutinib in a longer term follow up.
  • The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
星期三, 二月 28, 2024
Apps, Applications, Technology, Medical Devices, Other Technology, Health Technology, Software, Biotechnology, Health, Pharmaceutical, AML, G protein-coupled receptor, ASH, Investment, FEP, CDC7, Growth, Table, AbbVie, NLRP3, MALT1, Society, GAAP, Myelodysplastic syndrome, GPCR, Lymphoid leukemia, Solubility, Patient, Drug discovery, HERG, Acute myeloid leukemia, MBBS, IND, Research, Pharmaceutical industry

Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Key Points: 
  • Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.
  • For the first quarter of 2024, software revenue is expected to range from $33 million to $35 million.
  • “We had a very strong year in 2023, with significant growth in our software and drug discovery revenue and substantial progress in our proprietary pipeline and at our co-founded companies.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, at 4:30 p.m.

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 二月 27, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CD20, NSCLC, Cancer, J&J, Immune system, Alanine transaminase, Autoimmune disease, Research, ENPP3, Investment, ALT, PSMA, Cell, Antibody, Autoimmune hepatitis, Safety, Telephone, Vir, Lymphoid leukemia, Rash, Patient, PSA, RECIST, CLDN6, Diagnosis, Prostate-specific antigen, G&A, Workforce, CD28, Prostate cancer, Pharmaceutical industry

Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.

Key Points: 
  • Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.
  • In the fourth quarter of 2023, Xencor completed enrollment in subcutaneous dose-escalation cohorts of a Phase 1 study evaluating plamotamab.
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2023
    Cash, cash equivalents, and marketable debt securities totaled $697.4 million as of December 31, 2023, compared to $584.5 million on December 31, 2022.
  • Total revenue for the fourth quarter ended December 31, 2023 was $44.7 million compared to $21.6 million for the same period in 2022.